Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 11, 2013, Pages 1366-1374

  Sanchez Moya A I ^a   Garcia Doval I ^b   Carretero, G ^c   Sanchez Carazo J ^d   Ferrandiz, C ^e   Herrera Ceballos, E ^f   Alsina, M ^g   Ferran M ^h   Lopez Estebaranz J L ⁱ   Gomez Garcia F ^j   De La Cueva Dobao, P ^k   Carrascosa, J M ^e   Vanaclocha, F ^l   Belinchon I ^m   Peral, F ⁿ   Dauden, E ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Unidad de Investigación   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^j HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^k HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CHEMOPROPHYLAXIS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRIMARY INFECTION; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; PSORIASIS; SCREENING TEST; SPAIN; SYSTEMIC THERAPY; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; COHORT STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; INCIDENCE; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PSORIASIS; SEVERITY OF ILLNESS INDEX; SPAIN; TUBERCULOSIS;

EID: 84885959907     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12011     Document Type: Article

References (42)

1. Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I,. Pulmonary adverse events of anti-tumornecrosis factor-alpha antibody therapy. Am J Med 2006; 119: 639-646.
2. Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM,. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-675.
3. Puig L, Bordas X, Carrascosa JM, et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2009; 100: 277-286.
4. Pathirana D, Ormerod A, Saiag P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70.
5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
6. Sanchez-Moya AI, Dauden E,. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-alpha treatment: every new solution breeds new doubts. Br J Dermatol 2011; 164: 208-209.
7. Kardos M, Kimball AB,. Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting. J Am Acad Dermatol 2012; 66: 148-152.
8. Amerio P, Amoruso F, Bardazzi F, et al. Detection and management of latent tuberculosis infections before bilogic therapy for psoriasis. J Dermatolog Treat 2012; [Epub ahead of print].
9. (®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 2011; 164: 553.PubMed.
10. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800.
11. Garcovich S, Ruggeri A, D'Agostino M, et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 2011; 16 Sep Doi: 10.1111/j.1468-3083.2011.04220.x. [Epub ahead of print].
12. Rivera R, Garcia-Doval I, Carretero G, et al. BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report. Actas Dermosifiliogr 2011; 102: 132-141.
13. Grupo de trabajo de la Guía de Práctica Clínica sobre el Diagnõstico, el Tratamiento y la Prevenciõn de la Tuberculosis. Centro Cochrane Iberoamericano, coordinador. Guía de Práctica Clínica sobre el Diagnõstico, el Tratamiento y la Prevenciõn de la Tuberculosis. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Agència d′Informaciõ, Avaluaciõ i Qualitat en Salut (AIAQS) de Cataluña; 2009. Guías de Práctica Clínica en el SNS: AATRM N° 2007/26.
14. Lecluse LL, Naldi L, Stern RS, Spuls PI,. National registries of systemic treatment for psoriasis and the European 'Psonet' initiative. Dermatology 2009; 218: 347. PubMed -356.
15. Sanchez-Moya AI, Dauden E,. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol 2011; 25: 730-733.
16. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
17. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-528.
18. Tubach F, Salmon Céron D, Ravaud P, Mariette X,. The RATIO observatory: french registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine 2005; 72: 456. PubMed.
19. Rodríguez E, Villarrubia S, Díaz O, Hernández G, Tello O,. Situaciõn de la tuberculosis en España. Casos de tuberculosis declarados a la red nacional de vigilancia epidemiolõgica en 2009. Boletín epidemiolõgico semanal 2010; 18: 213. PubMed -216.
20. Huo R, Romanelli P,. Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis. Am J Clin Dermatol 2010; 11 (Supp l): 139.
21. Perlmutter A, Mittal A, Menter A,. Tuberculosisand tumour necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160: 8. PubMed -15.
22. Fortaleza GT, Brito Mde F, Santos JB, Figueiredo AR, Gomes P,. Splenic tuberculosis during psoriasis treatment with infliximab. An Bras Dermatol 2009; 84: 420-424.
23. Kitamura G, Mehr N, Anderson N, Sirichotiratana M,. A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. Dermatol Online J 2009; 15: 11.
24. Raval A, Akhavan-Toyserkani G, Brinker A, Avigan M,. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007; 147: 699-702.
25. Gori A, Fabroni C, Prignano F, Lotti T,. Unusual presentation of tuberculosis in an infliximab-treated patientwhich is the correct TB screening before starting a biologic? Dermatol Ther 2010; 23 (Suppl 1): S1.
26. Bieber J, Kavanaugh A,. Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol 2004; 22 (5 Suppl 35): S126-S133.
27. Raychaudhuri SP, Nguyen CT, Raychaudhuri SK, Gershwin ME,. Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev 2009; 9: 67-81.
28. Tsai TF, Chiu HY, Song M, Chan D,. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol 2012; 20 July Doi: 10.1111/j.1365-2133.2012.11162.x. [Epub ahead of print]
29. Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40: 756-759.
30. Belknap R, Reves R, Burman W,. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005; 9: 1057-1058.
31. Arend SM, Leyten EM, Franken WP, Huisman EM, Van Dissel JT,. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45: 1470-1475.
32. Solovic I, Sester M, Gomez Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185.
33. Aslanidis S, Pyrpasopoulou A, Douma S, Petidis K,. Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? Arthritis Rheum 2008; 58: 327-328.
34. Haddican MM, Koo JY,. Is tuberculin skin testing reliable during anti-tumor necrosis factor-alfa therapy? A case report and review of the literature. J Am Acad Dermatol 2011; 65: 195-197.
35. Silva LC, Silveira GG, Arnone M, et al. Decrease in Mycobacterium tuberculosis specific immuneresponses in patients with untreated psoriasis living in a tuberculosis endemic area. Arch Dermatol Res 2010; 302: 255-262.
36. Bay ML, Lehrer A, Bressanelli A, Morini J, Bottasso O, Stanford J,. Psoriasis patients have T-cells with reduced responsiveness to common mycobacterial antigens. FEMS Immunol Med Microbiol 1998; 21: 65-70.
37. Alcaide Megias J, Altet Gomez MN, Canela-Soler J, et al. A study of the tuberculous infection in adults. Rev Clin Esp 2003; 203: 321-328.
38. Lima EVdA, Duarte A, Marques C, Benard G, Lorena V, Gomes Y,. Investigation of latent tuberculosis infection in patients with psoriasis who are candidate for receiving immunobiological drugs. An Bras Dermatol 2011; 86: 716. PubMed.
39. Denkinger CM, Dheda K, Pai M,. Guidelines on interferon-α release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011; 17: 806-814.
40. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
41. Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761.
42. Gomez Reino J, Loza E, Andreu JL, et al. Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients. Reumatol Clin 2011; 7: 284-298.